X
More than 60,000 patients use Brite
4.6 stars
Your health finally understandable with Brite
Enter email and you're done. No subscription, no credit card.
Search, tap and you're done. Over 3,400 medicines.
Check, remind, get an overview.
Sarah K., 34
I finally understand my therapy. The app reminds me, answers my questions — and I don't feel alone with it anymore.
Methylphenidate, usually known as Ritalin, is the most commonly used medication worldwide for treating ADHD and at the same time one of the most controversial of all. About 4 to 5% of children and 2 to 3% of adults are affected by ADHD, many of them without a correct diagnosis (German figures, broadly similar across Western countries). With correctly diagnosed ADHD the risk of addiction is low — used improperly as "cognitive doping," the effect is not scientifically demonstrated, while the risks are real and possession without a controlled-drug prescription is a criminal offense.
See more detail.gif)
Methylphenidate is a controlled drug (controlled-drug prescription). Taking it without medical indication is a criminal offence. Cardiological clarification before therapy. In children, monitor growth. Last updated: May 2026.
Methylphenidate is the most frequently used ADHD medication worldwide and at the same time one of the most controversially discussed active substances of all. Below are the most important key facts for a quick orientation; the individual points are explained in detail in the following chapters.
| Property | Details |
|---|---|
| Active substance | Methylphenidate — a centrally acting stimulant (psychostimulant) |
| Trade names | Ritalin, Medikinet, Concerta, Equasym (various durations of effect); generics available |
| ATC code | N06BA04 — centrally acting sympathomimetics |
| Mechanism of action | Inhibition of the reuptake of dopamine and noradrenaline — raises the availability of these messenger substances in the prefrontal cortex, improves attention and impulse control |
| Main indication | ADHD (attention deficit/hyperactivity disorder) in children, adolescents, and adults; narcolepsy |
| Onset of effect | Immediate-release after about 30 min, max. effect after 1–2 h; duration of effect 3–4 h (immediate-release) to 10–12 h (Concerta prolonged-release) |
| Usual dose | Individually titrated; mostly 0.3–1 mg/kg body weight per day, max. about 60 mg/day (children) |
| Dosage form | Tablets, prolonged-release tablets, prolonged-release capsules |
| Prescription status | A controlled drug (Betäubungsmittel, BtM)! Prescription only on a controlled-drug prescription |
| Dependence risk | Low with appropriate ADHD therapy; considerable with misuse (snorted, high-dose) |
| Most important note | Multimodal therapy: medication + behavioural therapy + psychoeducation + structural measures |
Methylphenidate is a centrally acting stimulant (psychostimulant) and the most frequently used medication worldwide for the treatment of ADHD — the attention deficit/hyperactivity disorder. It is known above all under the brand name Ritalin, but there are numerous further preparations (Medikinet, Concerta, Equasym) and generics with different durations of effect.
Methylphenidate was first synthesised as early as 1944 and has been in use since the 1950s. Despite this long history, it is one of the most controversially discussed medications of all — between those who see it as indispensable help for people with ADHD and those who fear an over-medicalisation of normal childlike behaviour. We will classify this debate factually in a separate chapter.
Important to understand: methylphenidate is chemically related to amphetamines and is subject to strict legal regulations as a controlled drug (Betäubungsmittel, BtM). At the same time, the scientific evidence shows that with correctly diagnosed ADHD and the right use it is very effective and well controllable. The apparent contradiction — a stimulant that makes hyperactive children "calmer" — is explained by the underlying mechanism of action.
Methylphenidate inhibits the reuptake of dopamine and noradrenaline into the nerve cells — similar to how SSRIs do with serotonin. As a result, these two messenger substances stay available longer in the synaptic cleft and can work more strongly. Particularly relevant is the effect in the prefrontal cortex — the brain region responsible for attention, impulse control, planning, and self-regulation.
With ADHD there is — put simply — an underfunction of the dopaminergic and noradrenergic system in the prefrontal cortex. That explains the apparently paradoxical effect: while a stimulant works activatingly in most people, it improves self-regulation in people with ADHD — the attention becomes more focused, the impulsivity sinks, the inner restlessness decreases. The affected person seems "calmer" because they can control better, not because they are dampened.
Immediate-release methylphenidate works quickly — onset of effect after about 30 minutes, maximum effect after 1–2 hours, duration of effect 3–4 hours. Prolonged-release preparations release the active substance over 8–12 hours and enable a once-daily intake. The short half-life of the immediate-release active substance (2–3 hours) explains why multiple daily administrations or prolonged-release forms are necessary to achieve an even effect over the day.
Hardly any medication is discussed so emotionally. A factual classification of the most important points of contention:
There is something to this concern — the prescription figures have risen clearly in recent decades, and there are regional differences that point to over- and underdiagnosis. At the same time, ADHD is a well-documented neurobiological disorder with considerable suffering and long-term consequences (dropping out of school, accidents, addictions) when it remains untreated. The solution lies not in blanket rejection, but in careful diagnosis by clear criteria and a multimodal therapy approach (medication plus behavioural therapy, psychoeducation, school measures).
Here the facts are clear: with correctly diagnosed ADHD and appropriate oral intake, the dependence risk is low. The slow influx in the brain with oral administration produces no "kick". Studies even show that a treated ADHD lowers the later addiction risk — because the self-medication with other substances falls away. It looks different with misuse (snorting, injecting, high doses) — then methylphenidate has a considerable addiction potential (see the brain doping chapter).
Methylphenidate has been in use for over 60 years and is well researched. The most important long-term effects (growth, cardiovascular) are known and are monitored in the therapy. What is true: very long-term effects over decades are harder to investigate, and the therapy should be checked regularly for its continued necessity — with "trials off the medication" for review.
Conclusion: the controversy is partly justified (overdiagnosis risk), partly exaggerated (fear of addiction with correct use). The reasonable middle way: careful diagnosis, multimodal therapy, regular review — not blanket rejection or uncritical use.
Methylphenidate is a controlled drug (Betäubungsmittel, BtM) in Germany and is subject to the Narcotics Act (BtMG). That has concrete practical consequences:
This strict regulation is meant to curb misuse — but it also makes the therapy more bureaucratic for patients (more frequent doctor visits, restricted prescription amounts). With journeys abroad, the medical certificate should be obtained in good time.
The main indication. With ADHD from the age of 6, methylphenidate — embedded in a multimodal therapy concept (behavioural therapy, psychoeducation, parent training, school measures) — is the first-choice remedy with a moderate to severe form. It improves attention, reduces impulsivity and hyperactivity, and can clearly improve the school and social functioning.
ADHD does not automatically disappear in adulthood — about half of those affected have relevant symptoms as adults too. Methylphenidate is also approved for adult ADHD (if the diagnosis already existed in childhood or is clearly demonstrable) and can improve concentration, organisation, and emotional self-regulation.
With the sleep illness narcolepsy with pronounced daytime sleepiness, methylphenidate can be used for promoting wakefulness — today, however, often receded into the background in favour of newer substances (modafinil).
An important practical aspect: methylphenidate comes in many forms with different durations of effect. The right choice depends on the daily routine and the individual needs:
| Preparation type | Examples | Duration of effect | Use |
|---|---|---|---|
| Immediate-release | Ritalin, Medikinet | 3–4 hours | Fast onset of effect, flexible control, multiple daily intake |
| Prolonged-release medium-long | Equasym Retard, Medikinet Retard | 6–8 hours | Covers the school morning and afternoon |
| Prolonged-release long | Concerta | 10–12 hours | Once in the morning, covers the whole day (OROS technology) |
| Combination preparations | Various manufacturers | Variable | A proportion of immediately and delayed released active substance |
Practical advantage of prolonged-release preparations: the once-daily intake in the morning saves the intake at school (stigmatisation, organisational effort) and ensures a more even effect without "effect gaps" and rebound effects. The choice of preparation is made individually by the treating specialist.
The dosing of methylphenidate is individually titrated — there is no standard dose that suits everyone. It is begun low, then raised step by step until the best effect with the least side effects is reached:
An honest assessment: methylphenidate is one of the most effective medications in the whole of psychiatry — the effect sizes with ADHD are among the highest in the whole of medicine. In well-diagnosed cases, about 70 to 80 per cent of patients respond clearly.
What methylphenidate demonstrably improves: attention and concentration, impulse control, hyperactivity, working memory, school and occupational performance, social interaction. Studies also show a reduction of accidents, injuries, and — with long-term treatment — of later addictions and criminal behaviour.
The limits: methylphenidate does not cure ADHD — it treats the symptoms as long as it works. It does not replace the non-medication building blocks (behavioural therapy, structure, psychoeducation) that are decisive for the long-term success. And it does not work for everyone: with a non-response, alternatives come into question (lisdexamfetamine, atomoxetine, guanfacine). Important is the realistic expectation: methylphenidate is an effective building block, but no sole cure-all.
Methylphenidate has a known side-effect profile — most side effects are dose-dependent and well controllable. Commonly occurring side effects:
Rarer, but important:
One of the most important long-term questions in children. Methylphenidate can, through the reduction of appetite, lead to a temporary slowing of growth and weight gain. Studies show on average a slight reduction of the final height (often in the range of 1–3 cm), which, however, turns out very different individually.
